Pullan's Pieces #116

June 2016

Global BD News of Biotech and Pharma

Dear Reader,

If you like this newsletter, please sign up to get a monthly email.

SIGN UP HERE TO RECEIVE THESE MONTHLY NEWSLETTERS DIRECTLY IN YOUR INBOX
https://www.robly.com/subscribe?a=09d720be69e6cff000f5ff54cdae0b0bOr send me a note at This email address is being protected from spambots. You need JavaScript enabled to view it. .

Whoo! Since the last newsletter, there was ASCO and BIO!

Then a good webinar on due diligence, thanks to a great panel! You can watch the recording: http://resources.sharevault.com/webpanel-biopharma-due-diligence-pc

And so many term sheets in the works.

Hard to keep up. But fun!

- Linda Pullan

This email address is being protected from spambots. You need JavaScript enabled to view it. | 1(805)-558-0361 | www.PullanConsulting.com

 

Contents:

1.Best partners for big money?

2. Neuroscience snapshot

3. Top 100 VCs

4. Celebrate success in CML

Top Pharma and Big Biotech spend 70%+ of Alliance Deal Money- and Big Biotech pays more

Mark Edwards and the team at BioSci Advisors have again done a very useful analysis of licensing deals and who pays the most.

http://www.bioscibd.com/top-pharma-vs-major-biotech#1

 

DEAL TERMS OF IN-LICENSING DEALS by TOP PHARMA COMPANIES

Abbott, Abbvie, AZ, Baxter, Bayer, BMS, GSK, Lilly, Merck,

Merck Serono, Novartis, Novo, Pfizer, Roche, Sanofi, Takeda

image1 

 

 

 

 

 

 

 

 

 

 

 

 

DEAL TERMS OF IN-LICENSING DEALS by TOP BIOTECH COMPANIES

Actelion, Alexion, Alnylam, Amgen, Biogen, Biomarin,

Celgene, Gilead, Ilumina, Incyte, Ionis, Regeneron, Shire, Vertex

 June16 image 2

 

 

 

 

 

 

 

 

 

 

 

 

Infographic:  Neuroscience Snapshot

 June16  Image3

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Top 100 VCs for Life Science and Geography

June16  Image 4 

 

 

 

 

 

 

 

 

 

 

 

 

 

Most of the 2015 VC money for US biotechs comes from

California
Massachusetts
New York
And because VCs like to invest close to their offices, that is where most of the money ends up, too.

In the table below for top 100 VCs by 2015 investments,

June16  Image 5 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Celebrate an amazing success story- CML

 June16  Image 6

 

 

 

 

 

 

 

This is why we love our industry!  The life expectancy for patients diagnosed with the hematological cancer CML has now improved to match the life expectancy for the general population. This is true for males and females of all ages

If you like this newsletter, please sign up to get a monthly email.

SIGN UP HERE TO KEEP GETTING THE NEWSLETTER:
https://www.robly.com/subscribe?a=09d720be69e6cff000f5ff54cdae0b0b

Or send a note at This email address is being protected from spambots. You need JavaScript enabled to view it. .